Report of Foreign Issuer (6-k)
September 29 2016 - 7:43AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign
Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 29 September 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the
'
Company
')
Transaction
notification
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr K
Slaoui
|
|
b)
|
Position/status
|
PCA of
Dr M M Slaoui (Chairman, Global Vaccines)
|
|
c)
|
Initial notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the
financial
instrument
|
GlaxoSmithKline
plc American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of
the
transaction
|
Award
of ADSs under the Company's 2009 Share Value Plan
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
$43.58
|
2,300
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a
(single transaction)
|
|
e)
|
Date
of
the
transaction
|
2016-09-22
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mrs V A
Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the
financial
instrument
|
Ordinary
shares of 25 pence each 'Ordinary Shares'
ISIN:
GB0009252882
|
|
b)
|
Nature
of
the
transaction
|
Award
of Ordinary Shares under the Company's 2009 Share Value
Plan
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
11,060
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a
(single transaction)
|
|
e)
|
Date
of
the
transaction
|
2016-09-22
|
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: September
29, 2016
By: VICTORIA
WHYTE
----------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
